ClinicalTrials.gg
RecruitingNCT06323447PC002Updated Nov 3, 2026

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

An observational study in Diffuse Large B Cell Lymphoma and Multiple Myeloma, sponsored by Leuko Labs, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Leuko Labs, Inc. · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
210
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 216 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Planned enrollment
20th of 66
210 · median 84
Started
2025
with 27 others
Observational
66 of 1,131
12 open now
Primary completion
2027-06
later than 95 of 215 live
Registered
1,041st of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 20th largest by planned enrollment of the 66 observational ones that give a count, is one of 28 that started in 2025, is one of 66 observational ones, reaches primary completion later than 95 of the 215 other live ones, and was the 1,041st registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 10 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma
  • Multiple Myeloma
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This is a multi-site (4 US sites) observational open-label diagnostic study of a non-significant risk medical device, PointCheckTM. Participants (N=210) with specific malignancies who are scheduled to receive antineoplastic therapy will be evaluated during their routine management before the planned cytotoxic drug administration at two-time points (baseline and nadir evaluation). This will be an event-driven study with a total number of 70 positive cases (ANC \< 500 cells/mm3) and 140 negative cases (ANC >= 500 cells/mm3) has been considered sufficient to provide accurate estimates of Sensitivity and Specificity. They will have concurrent evaluations with PointCheckTM and a blood differential cell count in addition to the standard clinical visits. A subset (N=45) of patients will be evaluated for between-instrument reproducibility. Finally, a sub-study (N=30) will confirm the usability of PointCheckTM in the home setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the purpose and risks of the study and to provide signed and dated and authorization to use confidential health information in accordance with national and local subject privacy regulations.
  • Male or Female aged 10 years or above.
  • Diagnosed with either Diffuse Large B Cell Lymphoma or Multiple Myeloma.
  • Scheduled treatment with any antineoplastic therapy with an associated high/intermediate risk of neutropenia according to NCCN guidelines.
  • Able (in the investigator's opinion) and willing to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants with amputations, congenital malformations or any severe abnormalities of the hands as determined by the investigator.
  • Participants with a history of vasculitis, Raynaud syndrome, scleroderma, mixed connective tissue disease or any other rheumatologic systemic condition that could produce microcirculatory changes in the nailfold.
  • Participants with circulating tumour cells in previous or current lab determinations.
  • Participants with any condition producing significant tremor (e.g., essential tremor, Parkinson´s disease, dystonic tremor).
  • Unstable participants or participants with hypotension (systolic blood pressure \<90 and diastolic blood pressure \< 60mmHg).
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrolment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
210 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testPointCheck

    Binary classification of severe neutropenia

06

What researchers measure

Primary outcomes

  1. PointCheck Accuracy

    The main primary endpoints for this study will be the sensitivity and specificity of PointCheckTM to detect grade IV neutropenia ac cording to the CTCAE V5 definition of severe neutropenia in a standard blood analysis.

    Time frame: Two weeks

Secondary outcomes

  1. PointCheck Precision

    Repeatability and reproducibility will be assessed using the % positive/negative results of the test's classification compared to the gold standard after multiple measurements in different contexts.

    Time frame: Two-weeks

  2. PointCheck Usability

    Mean System Usability Score

    Time frame: Two-weeks

  3. PointCheck Errors

    Device related errors (number/type)

    Time frame: Two-weeks

  4. PointCheck Safety

    total number (and %) of AEs and SAEs related to the device use.

    Time frame: Two-weeks

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

Of 66 observational studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Mar 21, 2024
StartActual
Dec 15, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 3, 2026
Sites
6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • University of Hawaii Cancer Center · Honolulu, United Statesno status→Recruiting
  • Norton Healthcare Cancer Center · Louisville, United Statesno status→Recruiting
  • Massachussetts General Hospital · Boston, United Statesno status→Recruiting
  • Hackensack University Medical Center · Hackensack, United Statesno status→Recruiting
  • MDA · Houston, United Statesno status→Recruiting
  • Hospital Universitario 12 de Octubre · Madrid, Spainno status→Recruiting
Nov 3, 2026
Contact
Study contact now listed: added a•••@leuko.io · •••0974. See the current contact
Nov 3, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • University of Hawaii Cancer Center · Honolulu, United StatesContact added s•••@leuko.io · •••5799
  • Norton Healthcare Cancer Center · Louisville, United StatesContact added s•••@leuko.io · •••3366
  • Massachussetts General Hospital · Boston, United StatesContact added s•••@leuko.io · •••1612
  • Hackensack University Medical Center · Hackensack, United StatesContact added s•••@leuko.io · •••5855
  • MDA · Houston, United StatesContact added s•••@leuko.io · •••2860
  • Hospital Universitario 12 de Octubre · Madrid, SpainContact added s•••@leuko.io · •••8000
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Recruiting
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • University of Hawaii Cancer Center · Honolulu, United Statesno status→Recruiting
    • Norton Healthcare Cancer Center · Louisville, United Statesno status→Recruiting
    • Massachussetts General Hospital · Boston, United Statesno status→Recruiting
    • Hackensack University Medical Center · Hackensack, United Statesno status→Recruiting
    • MDA · Houston, United Statesno status→Recruiting
    • Hospital Universitario 12 de Octubre · Madrid, Spainno status→Recruiting
    Contact Study contact now listed: added a•••@leuko.io · •••0974. See the current contact
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • University of Hawaii Cancer Center · Honolulu, United StatesContact added s•••@leuko.io · •••5799
    • Norton Healthcare Cancer Center · Louisville, United StatesContact added s•••@leuko.io · •••3366
    • Massachussetts General Hospital · Boston, United StatesContact added s•••@leuko.io · •••1612
    • Hackensack University Medical Center · Hackensack, United StatesContact added s•••@leuko.io · •••5855
    • MDA · Houston, United StatesContact added s•••@leuko.io · •••2860
    • Hospital Universitario 12 de Octubre · Madrid, SpainContact added s•••@leuko.io · •••8000
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06323447
Lead sponsor
Leuko Labs, Inc.
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Dec 15, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Alvaro Sanchez-Ferro, MD, PhD
Contact
alvaro@leuko.io
+1 617 419 0974
Carlos Castro Gonzalez, PhD
principal investigator · Leuko Labs

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion